Previously treated cases tested for RR-/MDR-TB (%) in China
China: Previously treated cases tested for RR-/MDR-TB was 92.0% in 2024. ◆ Volatile
Previously treated cases tested for RR-/MDR-TB in China, 2006–2024
Source: World Health Organization, Global Health Observatory.
Analysis
In 2024, previously treated cases tested for rr-/mdr-tb in China stood at 92.0%.
That represents a change of up 1.1% on the previous year and up 70.4% over ten years.
Over the whole period, previously treated cases tested for rr-/mdr-tb in China peaked at 100.0% in 2018 and was at its lowest, 0.1%, in 2006.
That places China 79th out of 180 countries with data for 2024, putting it in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Previously treated cases tested for RR-/MDR-TB in China, year by year
| Year | Value | Change |
|---|---|---|
| 2006 | 0.1% | — |
| 2007 | 0.2% | +110.0% |
| 2012 | 13.0% | +6090.5% |
| 2013 | 32.0% | +146.2% |
| 2014 | 54.0% | +68.8% |
| 2015 | 64.0% | +18.5% |
| 2016 | 76.0% | +18.8% |
| 2017 | 69.0% | -9.2% |
| 2018 | 100.0% | +44.9% |
| 2019 | 88.0% | -12.0% |
| 2020 | 97.0% | +10.2% |
| 2021 | 92.0% | -5.2% |
| 2022 | 89.0% | -3.3% |
| 2023 | 91.0% | +2.2% |
| 2024 | 92.0% | +1.1% |
China compared with similar countries
- China's 92.0% is above the median for upper middle income countries, which is 92.0%, 1.0× the median. (52 countries reporting)
- China's 92.0% is above the median for East Asia & Pacific, which is 85.0%, 1.1× the median. (28 countries reporting)
Biggest year-on-year movements
Years where Previously treated cases tested for RR-/MDR-TB in China changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.
| Year | Change | From | To |
|---|---|---|---|
| 2012 | +6090.5% | 0.2% | 13.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.2% | 0.1% | 0.2% | 2 |
| 2010s | 62.0% | 13.0% | 100.0% | 8 |
| 2020s | 92.2% | 89.0% | 97.0% | 5 |
Countries ranked near China
More health data for China
- Un projection of annual infant deaths, annual growth rate -1.15 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.0985 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 2,029 deaths per 1,000 people (2090)
- Number of infants who die before age 1 4,642 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 10 (2025)
- Population ages 00-04, female, annual growth rate -8.22 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0159 units per person (2025)
- Population ages 00-04, male, annual growth rate -8.73 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is previously treated cases tested for rr-/mdr-tb in China?
- Previously treated cases tested for rr-/mdr-tb in China was 92.0% in 2024, according to World Health Organization, Global Health Observatory.
- What is the highest previously treated cases tested for rr-/mdr-tb recorded in China?
- The highest recorded value was 100.0% in 2018.
- What is the lowest previously treated cases tested for rr-/mdr-tb recorded in China?
- The lowest recorded value was 0.1% in 2006.
- How does China rank for previously treated cases tested for rr-/mdr-tb?
- China ranks 79th out of 180 countries with data for 2024.
- Is previously treated cases tested for rr-/mdr-tb rising or falling in China?
- Over the last ten years it is up 70.4%. The long-run trend across the full record is volatile.
- Where does this China data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Previously treated cases tested for RR-/MDR-TB (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 15 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).